<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2779">
  <stage>Registered</stage>
  <submitdate>20/05/2010</submitdate>
  <approvaldate>20/05/2010</approvaldate>
  <nctid>NCT01128153</nctid>
  <trial_identification>
    <studytitle>Saxagliptin Triple Oral Therapy</studytitle>
    <scientifictitle>A 24-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIIb Study to Evaluate Efficacy and Safety of Saxagliptin in Combination With Metformin and Sulfonylurea in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Combination of Metformin and Sulfonylurea</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CV181-117</secondaryid>
    <secondaryid>D1680L00006</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Saxagliptin
Treatment: drugs - Placebo

Experimental: Saxagliptin 5 mg once daily - 

Placebo Comparator: Placebo once daily - 


Treatment: drugs: Saxagliptin
5 mg tablet once daily for 24 weeks to be taken orally

Treatment: drugs: Placebo
tablet once daily for 24 weeks to be taken orally

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in HbA1c From Baseline to Week 24, Last Observation Carried Forward (LOCF) - Adjusted Mean Change in HbA1c from baseline to Week 24 using analysis of covariance model</outcome>
      <timepoint>From Baseline to Week 24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in 2-hour Postprandial Glucose (PPG) From Baseline to Week 24, Last Observation Carried Forward (LOCF) Measured as [mg/dL] - Adjusted Mean Change in 2-hour PPG from baseline to Week 24 using analysis of covariance model</outcome>
      <timepoint>From Baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in 2-hour Postprandial Glucose (PPG) From Baseline to Week 24, Last Observation Carried Forward (LOCF) Measured as [mmol/L] - Adjusted Mean Change in 2-hour PPG from baseline to Week 24 using analysis of covariance model</outcome>
      <timepoint>From Baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24, Last Observation Carried Forward (LOCF) Measured as [mg/dL] - Adjusted Mean Change in fasting plasma glucose from baseline to Week 24 using analysis of covariance</outcome>
      <timepoint>From Baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in Fasting Plasma Glucose (FPG) From Baseline to Week 24, Last Observation Carried Forward (LOCF) Measured as [mmol/L] - Adjusted Mean Change in FPG from baseline to Week 24 using analysis of covariance model</outcome>
      <timepoint>From Baseline to Week 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of Participants Achieving a Therapeutic Response: HbA1c Less Than 7% at Week 24, Last Observation Carried Forward (LOCF) - Number of participants achieving a glycaemic response defined as HbA1c less than 7% at Week 24</outcome>
      <timepoint>From Baseline to Week 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Written Informed Consent

          -  Males or females with type 2 diabetes with inadequate glycaemic control (HbA1c &gt; or =
             7% and &lt; or = 10%) despite being on combination of metformin and sulfonylurea for at
             least 8 weeks prior to Visit 1

          -  BMI &lt; or = 40 kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Symptoms of poorly controlled diabetes including but not limited to marked polyuria
             and marked polydipsia with &gt; 10% weight loss in 3 months prior to entry, or other
             signs and symptoms

          -  History of diabetic ketoacidosis or hyperosmolar non-ketotic coma

          -  Current or prior use within 3 months of Visit 1 of insulin, DDP4 inhibitor, GLP-1
             analogues, and/or other oral anti-diabetic agents (other than metformin or
             sulfonylurea)

          -  Treatment with CYP3A4 inducers and/or potent CYP3A4/5 inhibitor

          -  Estimated CrCl &lt; 60 ml/min at Visit 2

          -  CHF (NYHA class III or IV) and/or LVEF &lt;40%

          -  Active liver disease and/or significant abnormal liver function defined as AST and/or
             ALT &gt; 3 x ULN and/or bilirubin &gt; 2.0 mg/dL at Visit 2.

          -  Creatine kinase &gt; or = 10 x ULN at Visit 2</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>257</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Research Site - Broadmeadow</hospital>
    <hospital>Research Site - Wollongong</hospital>
    <hospital>Research Site - Daw Park</hospital>
    <hospital>Research Site - Elizabeth Vale</hospital>
    <hospital>Research Site - Melbourne</hospital>
    <hospital>Research Site - Camperdown</hospital>
    <hospital>Research Site - Herston</hospital>
    <postcode> - Broadmeadow</postcode>
    <postcode> - Wollongong</postcode>
    <postcode> - Daw Park</postcode>
    <postcode> - Elizabeth Vale</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Camperdown</postcode>
    <postcode> - Herston</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Newfoundland and Labrador</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Prince Edward Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Haryana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Karnataka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Madhya Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Maharashtra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Tamil Nadu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Kangwon-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Kyounggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Berks</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Cambridgeshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Kent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wiltshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Ashford</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Belfast</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Blackpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Chesterfield</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Coventry</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Peterborough</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wellingborough</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Bristol-Myers Squibb</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether the addition of saxagliptin to a patient's
      combination treatment of metformin and sulfonylurea for a 24 week period will provide better
      control of the patient's type 2 diabetes and will be well tolerated.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01128153</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jayanti Visvanthan, MD</name>
      <address>AstraZeneca</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>